Attached files

file filename
EX-99.1 - EX-99.1 - CYTOKINETICS INCexhibit1.htm






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   December 18, 2012

Cytokinetics, Incorporated
(Exact name of registrant as specified in its charter)

Delaware 000-50633 94-3291317
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
280 East Grand Avenue, South San Francisco, California   94080
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   (650) 624 - 3000

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On December 18, 2012, Cytokinetics, Incorporated (the "Company") received notification from the NASDAQ Listing Qualifications Department of the NASDAQ Stock Market ("NASDAQ") that the Company’s application to list its common stock on The NASDAQ Capital Market has been approved, and that the Company’s securities will be transferred from The NASDAQ Global Market to The NASDAQ Capital Market at the opening of the business on December 20, 2012. The NASDAQ Capital Market is one of the three markets for NASDAQ-listed stock and operates in the same manner as The NASDAQ Global Market. Companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to NASDAQ’s corporate governance standards. The Company’s common stock will continue to trade under the symbol "CYTK".

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Cytokinetics, Incorporated
December 18, 2012   By:   /s/ Sharon Barbari
        Name: Sharon Barbari
        Title: Executive Vice President, Finance and Chief Financial Officer

Exhibit Index

Exhibit No.   Description

  Press Release, dated December 18, 2012